Billion-Dollar Boost: Trends in Oncology Research and Development
Oncology has remained the top focus in biopharma research and development (R&D) dealmaking for several years. In recent times, deals in this sector have exceeded $200 billion, with 2022 alone accounting for $100 billion. Although the number of deals peaked in 2020 and 2021, the average value of these deals has increased, especially in 2024. However, deal numbers and values for 2024 are projected to remain comparable to 2023, with approximately 200 deals expected by year-end.
Most deals were at the platform/discovery stage, indicating a willingness to invest early in promising assets. The commitment to oncology R&D dealmaking remains strong as biopharma companies continue to prioritise cancer treatment advancements.
For more info on the present and future landscape of oncology research and development, view the full article here.
To reach and collaborate with potential partners and investors for your drug discovery, contact us about advertising with Biopharma Dealmakers.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
